跳到主要内容
Ruth

“我不想遭受同样的命运,我的母亲。”

露丝特立尼达,在mycode的鉴定BRCA2阳性

看她的故事 了解如何加入mycode的

mycode的社区健康计划

Anne Murphy
安妮·墨菲发现了通过mycode的她的遗传倾向的癌症。

我们不是在等待一天。今天我们的患者得到结果。

我们的基因组测序和辅导计划是在世界上首次大规模,卫生系统为基础的临床方案告知患者他们继承了基于他们的基因构成的疾病风险。

临床对方给我们 mycode的社区健康计划,我们的基因筛查和咨询程序赋予病人在我们的社会谁在早期发病癌症(乳腺癌,卵巢癌,结肠癌),早发心血管事件(心脏发作,中风)和其他潜在的可预防的疾病的高风险,更好地管理,甚至预防疾病。

Barbara Barnes

“mycode的救了我的命”

芭芭拉巴恩斯选择了接受手术去除她根据她的基因测试的结果生殖器官。 “如果我等了一年,我们就已经有一个完全不同的结果。”
了解mycode的

翻译遗传学为我们的患者并发语言

变体和基因策展

To interpret the results of genomic sequencing requires careful analysis of each genome variant discovered and what it might mean. The variant and gene curation teams at Geisinger are dedicated to accurately interpreting complex genomic data into meaningful knowledge for numerous research and clinical efforts. Additionally, leaders of Geisinger's Autism & Developmental Medicine Institute (ADMI) and Genomic Medicine Institute (GMI) are at the forefront of national and international efforts to standardize and streamline variant and gene curation processes. Through collaborative partnerships funded by the NIH, such as the Clinical Genome Resource (ClinGen) and the Electronic Medical Records and Genomics (eMERGE) Network, and other grants, members of our team are driving innovative efforts and helping to define high standards for all curation efforts. Geisinger remains a leader in these efforts to move precision health into everyday healthcare.